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Background—Kidney disease disproportionately affects minority populations including African 
Americans and Hispanics; therefore, understanding the relationship of kidney function to 
cardiovascular (CV) outcomes within different racial/ethnic groups is of considerable interest. We 
investigated the relationship between kidney function and CV events and assessed effect 
modification by race/ethnicity in the Women’s Health Initiative.
Study Design—Prospective cohort study
Setting & Participants—Baseline serum creatinine concentrations (assay traceable to isotope-
dilution mass spectrometry standard) of 19,411 postmenopausal women aged 50–79 years who 
self-identified as either non-Hispanic white (n=8921), African American (n=7436), or Hispanic 
(n=3054) were used to calculate estimated glomerular filtration rates (eGFRs).
Predictors—Categories of eGFR (exposure); race/ethnicity (effect modifier).
Outcomes—The primary outcome was the composite of three physician-adjudicated CV events: 
myocardial infarction (MI), stroke, or CV-related death.
Measurements—We evaluated the multivariable-adjusted associations between categories of 
eGFR and CV events using proportional hazards regression and formally tested for effect 
modification by race/ethnicity.
Results—Over a mean follow-up of 7.6 years, 1424 CV events (653 MI, 627 strokes, 297 CV-
related deaths) were observed. The association between eGFR and CV events was curvilinear; 
however, the association of eGFR with CV outcomes differed by race (P=0.006). In stratified 
analyses, we observed that the U-shaped association was present in non-Hispanic whites, whereas 
African American participants had a rather curvilinear relationship with lower eGFR being 
associated with higher CV risk and higher eGFR with reduced CV risk. Analyses among Hispanic 
women were inconclusive owing to few Hispanic women having very low or high eGFR and very 
few events occurring in these categories.
Limitations—Lack of urinary albumin measurements; residual confounding by unmeasured or 
imprecisely measured characteristics.
Conclusions—In postmenopausal women, the patterns of association between eGFR and CV 
risk differed between non-Hispanic whites and African American women.
INDEX WORDS
cardiovascular disease (CVD); CV risk; CV events; myocardial infarction (MI); stroke; CV death; 
renal function; estimated glomerular filtration rate (eGFR); serum creatinine; race/ethnicity; 
Hispanic; African American; kidney disease; Women’s Health Initiative (WHI)
Chronic kidney disease (CKD), defined by a glomerular filtration rate (GFR) <60 ml/min/
1.73m2 or an albumin-creatinine ratio (ACR) ≥ 30mg/g, affects over 25 million Americans 
and its prevalence is increasing.(1, 2) Both markers of kidney function are directly and 
independently associated with all-cause and cardiovascular (CV) mortality.(3, 4) 
Furthermore, evidence is accumulating that minority populations are disproportionately 
affected by kidney disease, with African Americans having a higher risk of CKD that is 
more likely to progress to end-stage renal disease (ESRD) compared to whites.(5) Faster 
Arce et al. Page 2
Am J Kidney Dis. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
kidney function decline and increased risk of ESRD also exist in Hispanics compared to 
non-Hispanics.(6, 7)
Recent evidence suggests that the association between CKD and CV outcomes may differ by 
race.(4, 8) While previous studies have reported gender differences in the associations of 
estimated glomerular filtration rate (eGFR) and albuminuria with CV and all-cause 
mortality, relatively little is known about the association between decreased kidney function 
and CV risk and its potential modification by race or ethnicity among postmenopausal 
women in the United States.(9–13) Because most of the existing studies have predominantly 
examined white women, more information is needed on women of other racial/ethnic 
groups.
The multiethnic Women’s Health Initiative (WHI) prospective cohort study of 
postmenopausal women, for whom creatinine concentrations were measured in a large 
subset at baseline, provides an opportunity to assess the associations of GFR with 
myocardial infarction (MI), stroke, and CV death. We hypothesized that these associations 
would differ among racial and ethnic groups.
Methods
Study Design and Population
The WHI is a large prospective, multicenter cohort study that focuses on strategies for 
preventing heart disease, breast and colorectal cancer, and osteoporotic fractures in 
postmenopausal women aged 50–79 years recruited from September 1993 through 
December 1998. Subjects were post-menopausal if they had had some combination of the 
following: hysterectomy, double oophorectomy, conclusion of menstrual bleeding, 
vasomotor symptoms, or prescribed hormone therapy. The WHI study consists of an 
observational study cohort and three clinical trial components (a hormone therapy 
component, a dietary modification component, and a calcium/vitamin D component). Details 
of the eligibility criteria, data collection, and ascertainment of health outcomes have been 
reported previously (see Item S1, available as online supplementary material, for WHI 
clinical trial and observational study design). (14, 15)
Our analysis was restricted to a subset of WHI participants who participated in the WHI 
Core Biomarker Studies, including 8,505 African American and 3,503 Hispanic participants 
who constituted the WHI Single Nucleotide Polymorphism (SNP) Health Association 
Resource (SHARe) cohort and 10,300 participants of European ancestry who had 
participated in the WHI Memory Study,(16) an ancillary study of the WHI hormone trials, 
or whose samples were analyzed in another WHI ancillary study, the Genomic and 
Randomized Trials Network (GARNET) study (Figure 1).(17) The African American and 
Hispanic participants in the SHARe cohort were drawn from the observational study and the 
clinical trial components. The participants of European ancestry were drawn from the 
hormone therapy components. The participants in these trials provided baseline data on 
various CV disease biomarkers including creatinine, cholesterol, HDL cholesterol, LDL 
cholesterol, triglycerides, insulin, glucose, and C-reactive protein. After excluding 
participants whose serum creatinine measurements were not available (n=197) and/or those 
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with missing data on covariates of interest (n=2,700), the final cohort included 19,411 
participants. There were no clear patterns of missingness in our covariates and none of the 
variables we excluded had missing rates greater than 5%.
Primary Exposure of Interest
The exposure of interest was eGFR at baseline. Stored frozen serum specimens were sent to 
the University of Minnesota–Fairview laboratory for measurement of baseline creatinine 
concentrations and other CV risk markers (see below). Serum creatinine was measured by 
the Roche enzymatic method on a Roche Modular P Chemistry Analyzer (Roche Diagnostic 
Corporation) and calibrated against an isotope-dilution mass spectroscopic standard.(18) 
Each patient’s GFR was then estimated using the CKD-EPI (CKD Epidemiology 
Collaboration) equation from her serum creatinine concentration, age, sex, and African 
American versus non-African American race. The CKD-EPI creatinine equation has been 
shown to provide a more accurate estimation of measured GFR compared with previously 
established creatinine-based equations.(19, 20) The eGFR was the exposure of interest in 
this study and, due to a small number of participants with eGFR <30 ml/min/1.73m2 (n=46; 
0.24%), participants were divided into the following six eGFR strata: <45, 45–<60, 60–<75, 
75–<90, 90–<105, and ≥105 ml/min/1.73m2.
Ascertainment of Outcomes
The primary outcome of interest was the composite of three CV events: MI, stroke, or death 
related to a CV event. Secondary outcomes of interest were the individual events that 
constituted the composite CV outcome. The diagnosis and adjudication of these outcomes 
have been previously described and outlined in established protocols (see Item S1 for CV 
adjudication information).(14)
Covariate of Interest: Effect Modifier
We sought to test for effect modification of the association between eGFR and CV events by 
self-identified race/ethnicity; participating women had the opportunity to select one of the 
following categories: non-Hispanic White, African American, Asian or Pacific Islander, 
Hispanic/Latino, American Indian or Alaskan Native, and other. It was not recorded in the 
WHI of what race self-identified Hispanic participants considered themselves. For the 
purpose of this report, we will refer to the categories as non-Hispanic white, African 
American, and Hispanic with the understanding that most African American women were 
likely non-Hispanic and most Hispanic women were white. Analyses were restricted to 
participants who reported one of these three categories because the participants from the 
SHARe, WHI Memory Study, and GARNET cohorts with data on CVD biomarkers only 
include women from these three categories.
Other Covariates: Demographic and Health Characteristics
Details of baseline self- or interview-administered study questionnaires, physical 
measurements, and blood measurement have been previously described.(14, 15) 
Standardized questionnaires administered at study entry ascertained sociodemographic 
characteristics including age, presence of diabetes, history of MI or stroke, drinking status 
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(none, past, current), and smoking status (current, past, non-smoker). Medical history was 
updated annually for women in the observational study or semiannually for women in the 
clinical trials by mail and/or telephone questionnaires.
Trained clinical center staff obtained anthropometric measurements at the baseline clinic 
visit. Height was measured with a calibrated stadiometer and weight with a calibrated scale, 
with participants in light clothing, without shoes. Body mass index (BMI) was calculated as 
weight in kilograms divided by height in square meters. Based on their BMI, individuals 
were classified as being underweight (BMI of <18.5 kg/m2), normal weight (BMI of 18.5–
24.9 kg/m2), overweight (BMI of 25.0 to 29.9 kg/m2) or obese (BMI of ≥30 kg/m2). Waist 
circumference was measured at the narrowest part of the torso and hip circumference at the 
maximal circumference. Seated systolic blood pressures were measured in the right arm 
using a conventional mercury sphygmomanometer after 5 minutes of rest, with an 
appropriate cuff size based on arm circumference measurement. Two blood pressure 
measurements were taken at least 30 seconds apart, and were averaged for the current 
analyses.
Physical activity (PA) at baseline was assessed using a validated 9-item measure of physical 
activity from the Personal Habits Questionnaire and was expressed in metabolic equivalent 
task (MET)-minutes per week.(21) Participants were categorized as sedentary, low, 
moderate, or high (0, 0.1–<5, 5–11.9, or ≥12 MET hours per week).
A quality of life measure characterizing physical function was taken from the results of a 36-
Item Short Form Health Survey (SF-36), which was administered at baseline. This construct 
ranges from 0 to 100, with higher values corresponding to better health.(22)
In addition to creatinine concentrations, C-reactive protein, total and HDL cholesterol, and 
triglyceride concentrations were also measured from stored biospecimens. The Friedewald 
equation(23) was used to calculate LDL concentration from total cholesterol, HDL 
cholesterol, and triglyceride concentrations.
Statistical Analyses
The goal of our analysis was to determine the relationships between baseline eGFR and 
composite and individual CV events in this multiethnic cohort of postmenopausal women 
with particular focus on examining racial/ethnic heterogeneity in all analyses. The 
relationships among eGFR categories and CV events were modeled using Cox proportional 
hazard regression, overall as well as stratified by racial/ethnic group. Participants who did 
not have a CV event or who died from non-CV causes were censored at the time of death or 
end of study period, whichever occurred first. The eGFR category with the lowest rate of 
CV events was chosen to be the referent group. We fit four models to estimate the hazard 
ratios (HRs) for the individual and composite CV outcomes: model 1 estimated unadjusted 
HRs; model 2 adjusted for age (categorical); model 3 additionally adjusted for presence of 
diabetes, history of stroke, and history of MI; model 4 additionally adjusted for BMI, 
lifestyle factors (physical activity, history of smoking, and antihypertensive and alcohol 
use), laboratory measurements (blood pressure, C-reactive protein, and LDL and HDL 
cholesterol), and SF-36 physical function score. All models were stratified by cohort (i.e. 
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observational study or clinical trial) to allow different baseline hazards for each cohort. 
Analyses were explored for violation of proportional hazards by stratification and inspection 
of the Kaplan-Meier plots for all outcomes and no apparent violations were observed. We 
examined log-log plots and calculated Schoenfeld residual p-values, and found no 
significant evidence of departure from the proportional hazards assumption. In the 
multivariable-adjusted Cox proportional hazards model 4, we formally tested for effect 
modification between race/ethnicity and eGFR category by using a Wald test to obtain an 
omnibus P-value for interaction between the eGFR categories and the 3 categories of race/
ethnicity. Within the interaction model, we also examined the individual contrasts between 
African Americans versus non-Hispanic whites and between Hispanics versus non-Hispanic 
whites. P-values for these interaction tests were assessed at the α <0.05 level of significance.
In order to assess the robustness of our results from a complete case analytic approach, 
missing data were imputed using SAS’s PROC IMPUTE, and fit using the primary analysis 
models in a sensitivity analysis.
Participants provided written informed consent, and study procedures and protocols were 
approved by the institutional review boards at the National Institutes of Health and at all 40 
participating institutions. Analyses were performed with SAS software, Version 9.4 (SAS 
Institute Inc., Cary, NC) and R 3.1.0 software (The R Foundation for Statistical Computing).
Results
Baseline Characteristics
From the WHI biomarker cohort, we identified 22,111 women aged 50–79 years who 
enrolled in the WHI study between 1993 and 1998 and had a valid serum creatinine 
concentration measured. Participants with missing covariates were excluded (n=2,700). 
Excluded participants were similar in age to those included (mean age, 63.5 ±7.4 (standard 
deviation) versus 63.9 ±7.3 years) but more likely to be non-Hispanic white (46.4 % versus 
45.8%). The eGFRs were similar for excluded and included participants (86.9 ±17.3) versus 
87.6 ±16.6 ml/min/1.73 m2). Excluded participants had a higher rate of CV events (9.5 vs. 
7.1 per 1000 years of follow-up).
The final analytic cohort of 19,411 women included 8921 (46.0%) non-Hispanic white, 7436 
(38.3%) African American, and 3054 (15.7%) Hispanic women (Figure 1). Baseline 
characteristics of the study participants stratified by eGFR categories and race/ethnicity are 
shown in Table 1. Given the large cohort, statistically significant differences were observed 
across racial/ethnic groups for all variables (all P<0.05). In general, participants with a 
lower eGFR were more likely to be older, have diabetes, and have a history of MI and 
stroke, and participants with lower eGFR were more likely to have dyslipidemia and higher 
C-reactive protein levels, irrespective of race and Hispanic ethnicity.
The distribution of eGFR, stratified by self-reported race/ethnicity, is shown in Figure 2. 
Women self-identifying as Hispanic had a higher median eGFR (93.9 [IQR, 82.5–100.5] 
ml/min/1.73m2) than that of non-Hispanic whites (85.7 [IQR, 74.4–92.6] ml/min/1.73m2) 
and eGFR comparable to that of African Americans (93.7 [IQR, 79.3–107.5] ml/min/1.73 
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m2). The range for eGFR values was widest for the African American participants and most 
narrow for the non-Hispanic white participants.
Study Outcomes
Over a mean follow-up period of 7.6 ±1.8 years, a total of 1392 women had one or more CV 
events of interest, including 622 MIs, 597 strokes, and 286 CV deaths (Table 2). For the 
composite outcome, we observed 1,360 events across 147,744 person-years of follow-up. Of 
note, within the highest eGFR category (≥105 mg/min/1.73 m2), no CV events were 
observed among self-reported Hispanic participants.
In Figure 3, we show the adjusted HRs of the composite CV event across categories of 
eGFR stratified by race and ethnicity. After adjustment for socio-demographic 
characteristics, comorbid conditions, lifestyle factors, and biometric/laboratory data, the 
association between eGFR and the composite CV end point was curvilinear in the overall 
cohort, but modified by race/ethnicity (P for interaction (omnibus test) =0.003). Stratum 
specific effect modification was found for race (African Americans vs. non-Hispanic whites, 
P=0.001), but not for ethnicity (Hispanics vs. non-Hispanic whites, P=0.4). Compared to the 
referent group with an eGFR of 75–<90 ml/min/1.73m2, non-Hispanic white participants 
had a U-shaped relationship between eGFR and CV events: both higher (≥105 ml/min/
1.73m2) and lower (<45 ml/min/1.73m2) eGFR were associated with higher event rates 
(HRs of 2.00 [95% CI, 1.24–3.24] and 1.60 [95% CI, 1.01–2.94], respectively) (Table S1). 
Among African American participants, however, a rather curvilinear relationship was 
observed; for the composite CV outcome, compared with participants with eGFR in the 75–
<90 ml/min/1.73m2 reference group, an eGFR of 90–<105 ml/min/1.73m2 was associated 
with a lower event rate (HR, 0.62; 95% CI, 0.47–0.83), and eGFR ≥105 ml/min/1.73m2 was 
associated with an even lower event rate (HR, 0.45; 95% CI, 0.33–0.62). On the other end of 
the eGFR spectrum, in the eGFR <45 ml/min/1.73m2 category, African American women 
had similar rates of composite CV events (HR, 1.46; 95% CI, 0.94–2.26) as those of non-
Hispanic white women, but the association was not significant. For the Hispanic 
participants, the relative rates of CV events could not be determined in the highest eGFR 
category (no events) and were not significantly different from the referent for eGFR 
categories ≤60 ml/min/1.73m2. However, Hispanic women had lower rates of composite CV 
events in the category of eGFR 90–<105 ml/min/1.73m2 (HR, 0.40; 95% CI, 0.27–0.59).
Analyses of individual CV events were naturally limited by fewer events and reduced 
power. The association between eGFR and MI in the full study sample was J-shaped and the 
omnibus test for interaction by race/ethnicity was of borderline significance (P=0.09). 
Stratum specific interaction was present for African American race vs. non-Hispanic whites 
(P=0.03) but not for self-reported Hispanic women vs. non-Hispanic whites (P=0.4). In a 
multivariable model adjusted for patient characteristics and CV risk factors, non-Hispanic 
whites with high eGFR (≥105 ml/min/1.73m2) had increased rates of MI (HR, 2.04; 95% CI, 
1.07–3.87), whereas both African Americans and Hispanics had reduced MI rates with more 
preserved eGFR compared to the reference group. No associations were found among the 
eGFR categories below 60 ml/min/1.73m2 for any of the racial and ethnic groups (Table 
S2).
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Non-Hispanic whites had higher adjusted rates of stroke at an eGFR <45 ml/min/1.73m2, 
compared to those in the referent eGFR category (HR, 2.09; 95% CI, 1.05–4.18) (Table S3). 
No significant associations were found in any of the other eGFR categories for whites. 
Stroke rates were lower for African Americans and Hispanics at an eGFR of 90 ml/min/
1.73m2 or higher.
For the outcome of CV death, an increased risk was observed at an eGFR <45 ml/min/
1.73m2 among non-Hispanic whites and <60 ml/min/1.73m2 among African Americans. 
Hispanic participants had very few events (n=17), leading to rather unstable estimates (Table 
S4).
The results of the sensitivity analyses using imputation methods did not differ meaningfully 
from the results of our main complete case analyses.
Discussion
In this large, multiethnic study of postmenopausal women, we confirmed associations 
between eGFR, a kidney disease marker, and CV risk. However, the patterns of association 
between eGFR and the composite CV outcome varied significantly between non-Hispanic 
whites and African Americans, with a U-shaped association for non-Hispanic whites and a 
rather curvilinear association for African Americans. The association between eGFR and 
CV events among Hispanics could not be evaluated in sufficient detail since there were only 
few Hispanic participants and even fewer CV events in the extreme eGFR categories. 
Analyses of individual CV events were naturally limited by reduced precision due to their 
small number, but found to be broadly compatible with the findings of the composite CV 
end point.
The strong relationship between CKD and CV risk is well established. In a landmark study 
using data from the Kaiser Permanente of Northern California, Go and colleagues described 
the detailed trajectory of CV risk across the spectrum of kidney function in adults 20 years 
of age or older. Compared with individuals with normal kidney function (eGFR ≥60 ml/min/
1.73m2, using the 4-variable MDRD [Modification of Diet in Renal Disease] Study 
equation), an independent, monotonic increase in the risk of CV events was observed for 
each successive stratum of GFR decline.(3) Moreover, recent studies have shown that the 
association between eGFR and CV risk is even stronger when using the more accurate 
CKD-EPI (CKD Epidemiology Collaboration) equation, or using equations based on 
measurements of cystatin C instead of or additional to serum creatinine concentrations.(19, 
20, 24)
Racial and ethnic disparities in the CV risk among individuals with CKD have previously 
been described.(7, 25) Peralta et al. found that among patients with eGFR <60 ml/min/
1.73m2, Hispanic individuals had 18% lower rates of CV events compared with otherwise 
similar non-Hispanic whites.(7) In a pooled analysis of community-based cohorts, Weiner et 
al. found effect modification by African American versus white race of the association 
between eGFR <60 ml/min/1.73m2 and a composite outcome of nonfatal CV events and all-
cause mortality.(8) However, the reference group included all individuals with eGFR ≥60 
Arce et al. Page 8
Am J Kidney Dis. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
ml/min/1.73m2 and did not use any finer categorization of eGFR, especially within the 
relatively normal range of eGFR where we have found significant racial differences.
The largest study on the subject to date was a recent investigation by the CKD Prognosis 
Consortium, where effect modification by race (white, African American, Asian) of the 
associations between kidney markers (eGFR, ACR) with mortality, CV mortality, and 
ESRD was evaluated.(26) African Americans constituted a small minority of the 1.1 million 
study subjects, but still numbered almost 50,000 individuals. Despite the large sample size, 
the only CV event studied (CV mortality) was relatively rare and led to wide confidence 
limits for African Americans, especially in the extreme ranges of eGFR. No effect 
modification was found between whites and African Americans; however, due to the 
imprecise estimates in the higher eGFR range, their confidence bands appear compatible 
with our finding of a curvilinear rather than U-shaped association between eGFR and CV 
events.
More recently, Gutierrez et al. identified racial differences in the association between ACR, 
the other marker of kidney disease, and CV events in the Reasons for Geographic and Racial 
Differences in Stroke (REGARDS) study. Ultimately, higher urinary albumin excretion was 
more strongly associated with incident coronary heart disease risk among African American 
individuals as compared to whites.(4) A similar analysis using data from the Atherosclerosis 
Risk in Communities (ARIC) study did not identify any racial differences in the association 
of ACR with CV risk. Interestingly, among study participants with ACR > 30 mg/g, women 
had increased CV risk compared to men (1.3- to 1.8-fold higher HR).(27) This sex-
albuminuria interaction on CV risk had previously been described in other cohorts.(13, 28)
In the general population, the risk of CVD among women increases after menopause, which 
is believed to result from loss of the protective effect of estrogen on lipids and vascular 
function or a consequence of older age.(29–31) Previous studies using the WHI cohort have 
investigated racial/ethnic differences in CVD risk and mortality—interestingly, no racial/
ethnic disparities were observed in the context of diabetes(32) and severe obesity.(33) Few 
studies have described the relationship of CVD among women burdened with CKD in the 
United States. In 2001, Shlipak and colleagues identified 2,763 postmenopausal women with 
established CV heart disease using data from the Heart and Estrogen/Progestin Replacement 
Study (HERS). After multivariable adjustment, both mild (1.2–1.4 mg/dl) and moderate 
(>1.4 mg/dl) elevations of serum creatinine were independently associated with a 60%–80% 
increased risk of CV events compared with in women with normal kidney function.(34) 
However, potential effect modification by race and ethnicity on the relationship between 
kidney and CV risk was not explored.
The paradoxically increased CV risk in patients with higher eGFR has been previously 
reported and attributed to frailty or muscle wasting secondary to illness, leading to decreased 
creatinine generation rather than high level of kidney function.(35) Our observation that this 
elevated CV risk with high eGFR concentrations is found in non-Hispanic whites, but not 
African Americans, is novel. While it is possible that African American WHI participants 
were less frail and had more preserved muscle mass, we adjusted for other markers of frailty 
or poor health and nutritional status including BMI, waist circumference, physical activity 
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level, and SF-36 Physical Function score. Although cystatin C has not been proven to be a 
superior biomarker compared to creatinine, it has a more linear relationship with CV 
outcomes in older adults, compared with creatinine, which may have a J- or U-shaped 
relationship.(36, 37) Future studies should examine whether the accuracy of creatinine-
based (or cystatin C-based) estimation equations among individuals with seemingly 
preserved kidney function differs among racial and ethnic groups.
This study had several limitations. First, urinary albumin measurements were not available 
in WHI to better discriminate kidney disease burden. This could introduce probable 
confounding; however, eGFR and ACR have been shown to be independent risk factors for 
CV events.(3) In addition, only single measurements of creatinine were available and so we 
were unable to account for error associated with random intra-individual variability, or to 
analyze kidney and CV disease progression over time. While race and ethnicity was 
collected prospectively, misclassification may have occurred. Furthermore, as with other 
studies using interval monitoring of participants’ health events, under-reporting of CV 
events may have occurred. However, recall bias was limited as CV outcomes were 
adjudicated by physicians following participant report.(38, 39) In addition, although the 
CKD-EPI equation is more accurate compared to the MDRD Study equation in estimating 
GFR and predicting CV risk, a lack of precision in GFR estimates > 90 mL/min/1.73m2 has 
been reported among the Black population.(40) Moreover, although we adjusted for various 
covariates at baseline, we cannot rule out the possibility of residual confounding by 
unmeasured confounders. In order to account for covariates, the analytic cohort differed 
from the eligible participants in that participants excluded from the analysis were more 
likely to be non-Hispanic white, thus introducing potential selection bias. Moreover, 
generalizability of our findings may be limited because the study only consisted of relatively 
healthy postmenopausal women. Finally, lack of recruitment of Hispanics with eGFR values 
in the lower and higher spectrum of kidney disease and small number of cases in several 
eGFR categories limited the power to detect effect modification for this ethnic group. This 
narrow eGFR range observed among Hispanic participants may have been the result of 
selection bias during recruitment and/or differential participant nonresponse (in particular a 
potentially lower response among sicker Hispanic women).
In conclusion, using a large, national, and prospectively assembled cohort of diverse, 
postmenopausal women, we found that the patterns of association between eGFR and CV 
outcomes varied by race/ethnicity—the association was U-shaped for non-Hispanic white 
women and more curvilinear for African American women. These findings add to the 
growing body of evidence on the racial differences in CV risk with reduced kidney function. 
Future studies, including ones using cystatin C-based estimations of glomerular filtration 
rate, need to confirm our findings of racially distinct patterns of CV risk from decreased 
kidney function.
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Figure 1. Flow Diagram of WHI CVD Biomarker Study Cohort
Our analysis was restricted to a subset of WHI participants who participated in the WHI 
Core Biomarker Studies, including 8,505 African American and 3,503 Hispanic participants 
who comprised the WHI Single Nucleotide Polymorphism (SNP) Health Association 
Resource (SHARe) cohort and 10,300 participants of European ancestry who had 
participated in the WHI Memory Study or whose samples were analyzed in another WHI 
ancillary study, the Genomic and Randomized Trials Network (GARNET) study.(17) The 
African American and Hispanic participants in the SHARe cohort were drawn from the 
observational study and the clinical trial components. The participants of European ancestry 
were drawn from the hormone therapy components. The participants in these trials provided 
baseline data on various cardiovascular disease biomarkers including creatinine. After 
excluding participants whose serum creatinine measurements were not available (n=197) 
and/or those with missing data on covariates of interest (n=2,700), the final cohort included 
19,411 participants. Abbreviations: SHARe, WHI SNP Health Association Resource; 
GWAS, Genome-Wide Association Study; WHIMS, WHI Memory study; GARNET, 
Genomic and Randomized Trials Network; CVD, cardiovascular disease.
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Figure 2. Distribution of Estimated Glomerular Filtration Rate by Racial/Ethnic Group
This figure shows the distribution of eGFR, stratified by self-reported race and ethnicity. 
Racial and ethnic groups were in mutually exclusive categories: African American, 
Hispanic, and non-Hispanic white. Women self-identifying as Hispanic had a higher median 
eGFR (93.9 [IQR, 82.5–100.5] ml/min/1.73m2) compared to non-Hispanic whites (85.7 
[IQR, 74.4–92.6] ml/min/1.73m2) and eGFR comparable to African American (93.7 [IQR, 
79.3–107.5] ml/min/1.73m2) participants. The range for eGFR values was widest for the 
African American participants and most narrow for the non-Hispanic white participants. 
Abbreviations: eGFR, estimated glomerular filtration rate (in mL/min/1.73m2).
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Figure 3. Associations between Estimated Glomerular Filtration Rate and Time to 
Cardiovascular Events (Myocardial Infarction, Stroke, Cardiovascular Death); Overall and by 
Racial/Ethnic Group
In the overall cohort, the association between eGFR and CV events curvilinear; effect 
modification by race and ethnicity was present in an omnibus test (P=0.006) as well as in a 
stratum-specific test for interaction by non-Hispanic white versus African American racial/
ethnic group membership (P=0.001). Stratum-specific interaction was not found between 
Hispanic versus non-Hispanic white racial/ethnic group membership (P=0.4). In stratified 
analyses, we observed that the U-shaped association was present in non-Hispanic whites, 
whereas black participants had a rather curvilinear relationship with lower eGFR being 
associated with reduced (CV risk) and higher eGFR with increased CV risk. Analyses 
among Hispanic women were inconclusive owing to few Hispanic women having very low 
or high eGFR and very few events occurring in these categories. Multivariable adjustment 
for HRs included age, presence of diabetes, history of stroke, history of myocardial 
infarction, body mass index, physical activity, physical function, history of smoking, history 
of alcohol use, C- reactive protein, blood pressure, use of antihypertensives, and LDL and 
HDL. Reference group was defined as eGFR 75–90 ml/min/1.73m2. Abbreviations: eGFR, 
estimated glomerular filtration rate (in mL/min/1.73m2).
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